Inhibrx Biosciences (NASDAQ:INBX) Trading Down 7% – Here’s What Happened

Posted by Brian Himes on Jul 10th, 2026

Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report)’s stock price was down 7% during mid-day trading on Friday . The stock traded as low as $97.30 and last traded at $96.5930. 52,007 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 328,462 shares. The stock had previously closed at $103.85.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Zacks Research upgraded shares of Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Wall Street Zen cut shares of Inhibrx Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Stifel Nicolaus assumed coverage on Inhibrx Biosciences in a research note on Wednesday, April 8th. They issued a “buy” rating and a $150.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $150.00.

Get Our Latest Stock Report on Inhibrx Biosciences

Inhibrx Biosciences Stock Performance

The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. The stock’s fifty day moving average is $103.11 and its 200-day moving average is $86.58. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -11.02 and a beta of 3.41.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.47). On average, analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current year.

Institutional Trading of Inhibrx Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Persistent Asset Partners Ltd acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter valued at approximately $27,000. Strs Ohio bought a new stake in Inhibrx Biosciences in the 1st quarter valued at $27,000. Public Employees Retirement System of Ohio bought a new position in shares of Inhibrx Biosciences in the third quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Inhibrx Biosciences by 26.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock worth $56,000 after acquiring an additional 147 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Inhibrx Biosciences by 71.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after purchasing an additional 789 shares during the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.